Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to PIC1-dPEG24 (ReAlta Life Sciences) for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The Food and ...

Lowering the body temperature of preterm infants (born at 33 to 35 weeks of pregnancy) with hypoxic ischemic encephalopathy (HIE)-a type of brain damage caused by oxygen loss-offers no benefits over ...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc., today announced that U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PIC1-dPEG24 for the treatment of ...

CINCINNATI – Inhibiting an enzyme in the brains of newborns suffering from oxygen and blood flow deprivation stops a type of brain damage that is a leading cause of cerebral palsy, mental retardation ...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases ...

Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not prevent death or disability, according to a new multinational study. The ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Erythropoietin ...

Perinatal asphyxia is the most important cause of neonatal mortality and serious sequel such as motor and cognitive deficits. The aim of this study is to investigate the effects of the melatonin and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A Virginia-based biotech company has ...

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...

Hypoxic ischemic encephalopathy is an important cause of neuropsychological deficits. Little is known about brain diffusivity in these infants following cooling and its potential in predicting outcome ...